World Health Organization Raises Warning Over Critical Lack of Obesity Injections

Fewer than 10% of patients that would benefit from obesity jabs such as Wegovy are able to get them, caution the global health agency as it publishes its first guidance on the medications.

Given in excess of 1,000,000,000 people worldwide now living with obesity, it is advocating for increased and just availability to this class of drugs.

Based on estimates, over two billion will be obese by 2030 if no action is taken.

"Our new guidance affirms that obesity is a chronic disease that can be addressed with comprehensive and lifelong care," said the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and distribution challenges are key hurdles to broad availability to the injections that can help people shift considerable body mass, notes the organization.

Skinny Jab Shortage

Even in the present most favorable outlook, the production of these medications might only reach about 100 million people – less than 10% of those who need them, per the WHO.

The recommendation encourages nations and manufacturers to expand availability, through strategies such as patent sharing.

A patent on the active ingredient – the main ingredient of Novo Nordisk's Wegovy – is set to lapse in multiple nations in 2026.

The Way Weight-Loss Injections Operate

These medications replicate a body's own hormone to delay gastric emptying, reduce hunger and increase satiety so people eat less.

People usually begin shedding pounds after several weeks of beginning the weekly injections.

Evidence indicates patients may regain a significant portion a year later of halting the medication, because their usual food cravings resume.

To be overweight or obese elevates your chance for contracting health problems, such as type 2 diabetes, heart disease, stroke, and certain cancers.

Obesity concerns individuals in every country and was associated with 3.7 million fatalities worldwide in 2024, as per the health agency.